Phenytoin (All indications)

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9246
R32080		 Tomson (Phenytoin), 2018 Cleft lip or palate at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 2.88 [0.15;56.08] C 0/125   3/2,514 3 125
ref
S10229
R37474		 Hernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012 Oral clefts 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No Controls: mixed indications 1.07 [0.22;5.19] C 2/416   7/1,562 9 416
ref
S9238
R32058		 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 Facial cleft 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 7.98 [0.49;128.74] C 1/82   1/647 2 82
ref
Total 3 studies 1.91 [0.55;6.62] 14 623
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Phenytoin), 2018Tomson, 2018 1 2.88[0.15; 56.08]312518%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Hernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012Hernández-Díaz, 2012 2 1.07[0.22; 5.19]941662%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 3 7.98[0.49; 128.74]28220%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.91[0.55; 6.62]146230.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Phenytoin; 2: Phenytoin) (Controls exposed to Lamotrigine, sick; 3: Phenytoin) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.91[0.55; 6.62]146230%NATomson (Phenytoin), 2018 Hernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 3 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 1.91[0.55; 6.62]146230%NATomson (Phenytoin), 2018 Hernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 3 Tags Adjustment   - No  - No 1.91[0.55; 6.62]146230%NATomson (Phenytoin), 2018 Hernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 3 Controls   - mixed indications  - mixed indications 1.07[0.22; 5.19]9416 -NAHernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012 1 All studiesAll studies 1.91[0.55; 6.62]146230%NATomson (Phenytoin), 2018 Hernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 30.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.91[0.55; 6.62]146230%NATomson (Phenytoin), 2018 Hernández-Díaz (Phenytoin) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Phenytoin) (Controls exposed to Lamotrigine, sick), 2006 30.510.01.0